NEW YORK (GenomeWeb) – PerkinElmer reported after the close of the market on Thursday that its first quarter revenues rose 3 percent year over year, thanks largely to an 8 percent revenue growth in its diagnostics business.

For the three months ended April 2, the company reported revenues of $514.1 million, up from $498.0 million a year earlier, and beating the average Wall Street analyst estimate of $506.8 million. Organic revenues increased 4 percent year over year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.